CN106520778A - 改造的白介素12及其在制备治疗肿瘤的药物中的用途 - Google Patents

改造的白介素12及其在制备治疗肿瘤的药物中的用途 Download PDF

Info

Publication number
CN106520778A
CN106520778A CN201510568718.5A CN201510568718A CN106520778A CN 106520778 A CN106520778 A CN 106520778A CN 201510568718 A CN201510568718 A CN 201510568718A CN 106520778 A CN106520778 A CN 106520778A
Authority
CN
China
Prior art keywords
tumor
modified interleukin
interleukin
recombinant vector
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510568718.5A
Other languages
English (en)
Chinese (zh)
Inventor
王尧河
王鹏举
高冬玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou University
Original Assignee
Zhengzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou University filed Critical Zhengzhou University
Priority to CN201510568718.5A priority Critical patent/CN106520778A/zh
Priority to CN202410669656.6A priority patent/CN118852455A/zh
Priority to CN201680022405.2A priority patent/CN108307642B/zh
Priority to PCT/CN2016/098527 priority patent/WO2017041739A1/zh
Priority to CN202311154075.0A priority patent/CN117736296A/zh
Priority to JP2018532498A priority patent/JP7340222B2/ja
Priority to CN202410669647.7A priority patent/CN118791625A/zh
Priority to US15/758,853 priority patent/US11345732B2/en
Priority to EP16843677.2A priority patent/EP3348643B1/en
Publication of CN106520778A publication Critical patent/CN106520778A/zh
Priority to JP2021215459A priority patent/JP7438552B2/ja
Priority to US17/700,991 priority patent/US20220213161A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201510568718.5A 2015-09-09 2015-09-09 改造的白介素12及其在制备治疗肿瘤的药物中的用途 Pending CN106520778A (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201510568718.5A CN106520778A (zh) 2015-09-09 2015-09-09 改造的白介素12及其在制备治疗肿瘤的药物中的用途
JP2018532498A JP7340222B2 (ja) 2015-09-09 2016-09-09 腫瘍溶解性ウイルス、腫瘍溶解性ウイルスを含む薬物、医薬品の製造における使用、および腫瘍溶解性ウイルスの作製方法
CN201680022405.2A CN108307642B (zh) 2015-09-09 2016-09-09 改造的白介素12及其在制备治疗肿瘤药物中的用途
PCT/CN2016/098527 WO2017041739A1 (zh) 2015-09-09 2016-09-09 改造的白介素12及其在制备治疗肿瘤药物中的用途
CN202311154075.0A CN117736296A (zh) 2015-09-09 2016-09-09 改造的溶瘤病毒及其用途
CN202410669656.6A CN118852455A (zh) 2015-09-09 2016-09-09 改造的白介素12、包含其的药物及其用途
CN202410669647.7A CN118791625A (zh) 2015-09-09 2016-09-09 包含改造的白介素12的溶瘤病毒及其用途
US15/758,853 US11345732B2 (en) 2015-09-09 2016-09-09 Modified interleukin 12 and use thereof in preparing drugs for treating tumours
EP16843677.2A EP3348643B1 (en) 2015-09-09 2016-09-09 Modified interleukin 12 and use thereof in preparing drugs for treating tumours
JP2021215459A JP7438552B2 (ja) 2015-09-09 2021-12-29 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用
US17/700,991 US20220213161A1 (en) 2015-09-09 2022-03-22 Modified interleukin 12 and use thereof in preparing drugs for treating tumours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510568718.5A CN106520778A (zh) 2015-09-09 2015-09-09 改造的白介素12及其在制备治疗肿瘤的药物中的用途

Publications (1)

Publication Number Publication Date
CN106520778A true CN106520778A (zh) 2017-03-22

Family

ID=58240596

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201510568718.5A Pending CN106520778A (zh) 2015-09-09 2015-09-09 改造的白介素12及其在制备治疗肿瘤的药物中的用途
CN201680022405.2A Active CN108307642B (zh) 2015-09-09 2016-09-09 改造的白介素12及其在制备治疗肿瘤药物中的用途
CN202410669656.6A Pending CN118852455A (zh) 2015-09-09 2016-09-09 改造的白介素12、包含其的药物及其用途
CN202410669647.7A Pending CN118791625A (zh) 2015-09-09 2016-09-09 包含改造的白介素12的溶瘤病毒及其用途
CN202311154075.0A Pending CN117736296A (zh) 2015-09-09 2016-09-09 改造的溶瘤病毒及其用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201680022405.2A Active CN108307642B (zh) 2015-09-09 2016-09-09 改造的白介素12及其在制备治疗肿瘤药物中的用途
CN202410669656.6A Pending CN118852455A (zh) 2015-09-09 2016-09-09 改造的白介素12、包含其的药物及其用途
CN202410669647.7A Pending CN118791625A (zh) 2015-09-09 2016-09-09 包含改造的白介素12的溶瘤病毒及其用途
CN202311154075.0A Pending CN117736296A (zh) 2015-09-09 2016-09-09 改造的溶瘤病毒及其用途

Country Status (5)

Country Link
US (2) US11345732B2 (enExample)
EP (1) EP3348643B1 (enExample)
JP (2) JP7340222B2 (enExample)
CN (5) CN106520778A (enExample)
WO (1) WO2017041739A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018184484A1 (zh) * 2017-04-06 2018-10-11 张晋宇 细胞因子组合
WO2021249035A1 (zh) * 2020-06-10 2021-12-16 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
TW202039851A (zh) * 2018-12-21 2020-11-01 美商特斯通生物技術公司 經修飾正痘病毒載體
CA3157024A1 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2023238106A1 (en) * 2022-06-10 2023-12-14 Transgene Recombinant virus expressing interleukin-12
WO2025221669A1 (en) * 2024-04-18 2025-10-23 Promab Biotechnologies, Inc. Fusion protein comprising il-12 and gm-csf

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142855A1 (en) * 2005-06-30 2009-06-04 Wei Tang Polynucleotides and Polypeptides of the IL-12 Family of Cytokines
RU2304586C1 (ru) * 2006-03-27 2007-08-20 Михаил Николаевич Смирнов Препарат интерлейкина-2 и способ его получения
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US20170291934A1 (en) * 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
MX2018004479A (es) * 2015-10-14 2019-07-10 Mighty Oak Medical Inc Aparato adaptado al paciente y metodos para realizar procedimientos quirurgicos.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018184484A1 (zh) * 2017-04-06 2018-10-11 张晋宇 细胞因子组合
CN110603048A (zh) * 2017-04-06 2019-12-20 张晋宇 细胞因子组合
US11535656B2 (en) 2017-04-06 2022-12-27 Jinyu Zhang Cytokine combination
WO2021249035A1 (zh) * 2020-06-10 2021-12-16 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用

Also Published As

Publication number Publication date
CN118791625A (zh) 2024-10-18
CN117736296A (zh) 2024-03-22
JP7438552B2 (ja) 2024-02-27
EP3348643A4 (en) 2019-03-06
WO2017041739A1 (zh) 2017-03-16
EP3348643A1 (en) 2018-07-18
US11345732B2 (en) 2022-05-31
CN108307642B (zh) 2024-04-26
JP7340222B2 (ja) 2023-09-07
CN108307642A (zh) 2018-07-20
JP2018533970A (ja) 2018-11-22
US20220213161A1 (en) 2022-07-07
JP2022061989A (ja) 2022-04-19
EP3348643B1 (en) 2022-03-02
US20190010200A1 (en) 2019-01-10
CN118852455A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
CN106520778A (zh) 改造的白介素12及其在制备治疗肿瘤的药物中的用途
CN102174479B (zh) 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
KR102409147B1 (ko) 종양분해성 백시니아 바이러스
JP2020011966A (ja) 増強された養子細胞療法
EP3453401A1 (en) Interleukin combination and use thereof
US12409217B2 (en) Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties
CN108686202A (zh) 肿瘤免疫疗法
US12357672B2 (en) Protein molecule of interleukins 12a and b combined with additional factors
JP2018509914A (ja) 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用
JP2007020586A5 (enExample)
Wang et al. Viral vectors expressing interleukin 2 for cancer immunotherapy
JP2015506697A (ja) １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
JP2020517692A5 (enExample)
WO2018137643A1 (zh) 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途
CN102038958A (zh) 一种纳米粒子组合物及其应用
CN117660368B (zh) 表达趋化因子ccl19的重组溶瘤流感病毒及应用
US12421502B2 (en) Enhanced adoptive cell therapy
KR20040097249A (ko) 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제
Rasoul et al. Use of viral vector to deliver IL-15 for cancer therapy: An overview
CN115702940A (zh) 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用
CA3241210A1 (en) Encapsulated cells expressing il-12 and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170322